Difference between revisions of "Work Product for Review"

From QIBA Wiki
Jump to navigation Jump to search
Line 16: Line 16:
 
*[[Media:001.QIBA SPECT Profile.v0.1 2016.10.28.docx | QIBA Profile: <font color=red>Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016</font>]]  
 
*[[Media:001.QIBA SPECT Profile.v0.1 2016.10.28.docx | QIBA Profile: <font color=red>Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016</font>]]  
 
*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|QIBA Profile Checklist: <font color=red>SPECT Profile Conformance</font>]]
 
*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|QIBA Profile Checklist: <font color=red>SPECT Profile Conformance</font>]]
 +
  
 
''Public Comment closed''
 
''Public Comment closed''

Revision as of 22:14, 9 February 2017

QIBA Profile documents are posted for Public Comment to ensure stakeholder representation, transparency and quality review. Interested people are encouraged to provide input on the document, the scenarios and use cases they address, the technologies proposed and other details.

Comment Submission

  • Select the document you are commenting on from the dropdown menu
  • Provide your name or initials
  • Follow the other instructions on the page
  • CLICK SUBMIT
  • e-mail (Susan Weinmann) with general comments about the Profile/Protocol concept, structure, process, etc.

The QIBA Biomarker Committees consider all comments submitted, and where appropriate, post responses.

Public Comment Documents

Public Comment closes March 1, 2017


Public Comment closed